Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes
worldwide. The number affected is increasing rapidly with alarming trends in children and …

Currently, metformin is the first-line medication to treat type 2 diabetes mellitus (T2DM) in
most guidelines and is used daily by> 200 million patients. Surprisingly, the mechanisms …

Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the
first-choice drug used daily by approximately 150 million people. An accumulation of …

Diabetes mellitus (DM) is a metabolic disorder that is one of the most common health
problems in the world, primarily type 2 DM (T2DM). Metformin (MTF), as the first-line …

Aims/hypothesis This study explored the hypothesis that significant abnormalities in the
metabolism of intestinally derived lipoproteins are present in individuals with type 2 diabetes …

Hematologic malignancies (HMs) mainly include acute and chronic leukemia, lymphoma,
myeloma and other heterogeneous tumors that seriously threaten human life and health …

Aims To compare the cardiovascular, renal and safety outcomes of second‐line glucose‐
lowering agents used in the management of people with type 2 diabetes. Methods …

Evidence‐based guidelines provide the premise for the delivery of quality care to preserve
health and prevent disabilities and premature death. The systematic gathering of …

Dicyandiamide (DCD) reacted with amino acids 1a–f to produce biguanides 2 and 4 and
guanidine pyrazolones 3, 5, 6, 7, and 8, according to the reaction. DCD exhibited the …

Metformin is of great focus because of its high safety, low side effects, and various effects
other than lowering blood sugar, such as anti-inflammation, anti-tumor, and anti-aging …